AB AB Science SA

AB Science announces that results from masitinib study AB07015 in severe asthma have been selected for presentation at an ATS symposium held on 16th October, 2020

AB Science announces that results from masitinib study AB07015 in severe asthma have been selected for presentation at an ATS symposium held on 16th October, 2020
EN
13/10/2020

Underlying

ABAB Science SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AB Science SA

 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science announces the successful completion of a 2.55 million euros...

AB Science announces the successful completion of a 2.55 million euros private placement PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.55 MILLION PRIVATE PLACEMENT Paris, August 4, 2025, 8am CET AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors (the “Private Placement”). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authori...

August 4, 2025 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science annonce le succès d’un placement privé d’environ 2,55 milli...

AB Science annonce le succès d’un placement privé d’environ 2,55 millions d’euros COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE D’ENVIRON 2,55 MILLIONS D’EUROS Paris, 4 août 2025, 8h AB Science S.A. (la “Société” ou “AB Science”, Euronext – FR0010557264 – AB) annonce aujourd'hui le succès d'une augmentation de capital d'un montant brut total de 2,55 millions d’euros souscrite par un nombre limité d'investisseurs (le « Placement Privé »). Le Placement Privé n'est pas soumis à un prospectus nécessitant un visa de l'Autorité des Marchés Financiers (l' « ...

August 4, 2025 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science receives regulatory approval from European countries to ini...

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML PRESS RELEASE AB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 TARGETING MICROTUBULE AND STEM CELLS AND VENETOCLAX TARGETING BCL-2 SHOWS POTENTIAL SYNERGISTIC EFFICACY AND GOOD HEMATOLOGICAL TOLERANCE COMPARED WITH STANDARD OF CARE CHEMOTHER...

July 30, 2025 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science a reçu l’approbation règlementaire de pays européens pour i...

AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA COMMUNIQUÉ DE PRESSE AB SCIENCE A RECU L’APPROBATION REGLEMENTAIRE DE PAYS EUROPEENS POUR INITIER LA TROISIEME ETAPE DE LA PHASE I/II VISANT A COMBINER SA MOLÉCULE AB8939 AVEC LE VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË LA COMBINAISON D’AB8939 CIBLANT LES MICROTUBULES ET LES CELLULES SOUCHES ET DE VENETOCLAX CIBLANT BCL-2 PRESENTE UN POTENTIEL D’EFFICACITE SYNERGIQUE ET DE BO...

July 30, 2025 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science has received approval from several European countries to in...

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL VALIDATION BY THE EMA AND FDA AUTHORIZATION Paris, July 24, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosis (ALS), study AB23005, has been authorized by th...

July 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch